George Martin’s quote seems rather apt this morning as NextCure announced there was disappointing single agent activity with their Siglec–15 directed agent (NC318) in an ongoing phase 1/2 trial.
There were a couple of initial partial responses reported at SITC last year and now it may seem as if the wheels are falling off the wagon.
What can we learn from the latest update?
It turns out quite a bit…
To learn more from our oncology analysis and get a heads up on insights and commentary emerging from recent events, subscribers can log-in or you can click to gain access to BSB Premium Content.
National Harbor, MD
With the abstract drop from the 2019 Society for the Immunotherapy of Cancer (SITC) meeting now available, what can we learn from some of the research slated for formal oral presentation this year?
Here in part one (posters will be reviewed tomorrow) we take a look at a mix of preclinical and early clinical studies that grabbed our initial interest from the oral presentations – they include the good, bad, and intriguing – to see exactly what can be learned from this year’s mix of abstracts?
The short answer is quite a lot.
Every year the what to watch out for preview is a popular one. This year there are some surprises in store as well as some particularly important findings that BSB readers may well be keen to find out more about ahead of the conference later this week in order to maximise their thinking and avoid the inevitable brain-fry and fatigue that sets in on Saturday afternoon…
To learn more from our oncology coverage and get a heads up on insights from our SITC19 commentary, subscribers can log-in or you can click to gain access to BSB Premium Content.
We’re continuing our mini-series on cracking the ‘glyco-code’ with an interview with Dr Lieping Chen (Yale), one of the world’s leading cancer immunologists, someone who has taken basic science and translated it into a spin-off company, NextCure (NASDAQ: NXTC) and a new product (NC318) targeting Siglec-15 that’s already being evaluated in the clinic.
Will upregulation of Siglec-15 turn out to be key in some cancer patients?
What happens if you identify a novel target that is expressed in a subset of patients that’s key to resetting the immune response and overcoming the immuno-suppressive tumor microenvironment (TME)?
Not only that, but you can potentially use a biomarker to select the patients most likely to benefit from what we’re calling a ‘targeted immunotherapy’ that’s directed at overcoming a specific immune dysfunction or defect.
Think of it as like when you press the factory re-set button on your iPad or iPhone.
Over the course of the coming year, we expect to hear a lot more about the early clinical data for this novel approach so in this expert interview we’re talking to the founder about the science that’s propelling NextCure forward.
To learn more from out latest oncology expert interview and get a heads up on their candid perspectives, subscribers can log-in or you can click to gain access to BSB Premium Content.